Loading patent…
AssigneeBiomerieux
InventorsLiliana Tejidor, Trevor Baglin, Hema Doobay, Roger Luddington, Timothy J. Fischer
Estimating the term…
A reagent and kit are disclosed for determining if a patient is hypercoagulable, hypocoagulable or normal. The test involves providing a test sample from the patient and initiating coagulation in the sample in the presence of an activator, which is added to the sample in an amount which will result in intrinsic tenase-dependent fibrin. Then the formation of the intrinsic tenase-dependent fibrin polymerization is monitored over time so as to derive a time-dependent profile, with the results of the fibrin polymerization monitoring determining whether the patient is hypercoagulable, normal or hypocoagulable. The coagulation activator is added in an amount that triggers a thrombin explosion that is dependent on the propagation phase and amplification pathways. In this way, a single assay can assess the hemostatic potential of a sample.
A reagent for an assay to determine a hemostatic potential of a blood or plasma sample, said reagent comprising a coagulation activator wherein said activator is present at a concentration level to trigger a thrombin formation but not to result in a complete fibrin polymerization of said blood or plasma sample, wherein said reagent is utilized to assess a hypocoagulable, normal hypercoagulable condition in a single assay.
A reagent comprising;
Dependencies are inferred from the claim text.